Bendamustine Plus Rituximab Versus CHOP Plus Rituximab
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00991211 |
Recruitment Status :
Completed
First Posted : October 7, 2009
Last Update Posted : March 14, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Non-Hodgkin Lymphomas Follicular Lymphomas Immunocytomas Lymphocytic Lymphomas Marginal Zone Lymphomas | Drug: Bendamustine Drug: Standard chemotherapy CHOP + Ritiximab | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 549 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Prospective Randomised Multicenter Study for Therapy Optimization (First Line) of Advanced Progredient, Low Malignant Non-Hodgkin Lymphomas and Mantle Cell Lymphomas |
Study Start Date : | January 2004 |
Actual Primary Completion Date : | August 2009 |
Actual Study Completion Date : | August 2009 |
Arm | Intervention/treatment |
---|---|
Experimental: Bendamustine + Rituximab
Bendamustine 90 mg/m² d 1+2 + Rituximab 375 mg/m² d 1 q4w
|
Drug: Bendamustine
Comparison of Bendamustine + Rituximab with CHOP + Rituximab
Other Name: Ribomustin, Treanda |
Active Comparator: CHOP + Rituximab
Cyclophosphamid 750 mg/m² d 1 + Doxorubicin 50 mg/m² d 1 + Vincristin 1,4 mg/m² max. 2 mg d 1 + Prednison 100 mg absolute p.o. d 1-5 + Rituximab 375 mg/m² d 1 q3w
|
Drug: Standard chemotherapy CHOP + Ritiximab
Cyclophosphamid 750 mg/m² d 1 + Doxorubicin 50 mg/m² d 1 + Vincristin 1,4 mg/m² max. 2 mg d 1 + Prednison 100 mg absolute p.o. d 1-5 + Rituximab 375 mg/m² d 1 q3w as standard Chemotherapy
Other Names:
|
- Progression free survival [ Time Frame: observation 3 years or significant differences between two arms ]
- Determination and comparison of remission rates, of toxicity, infectious complications, overall survival, EFS, TTNT, capacity of peripheral blood stem cell mobilization [ Time Frame: ongoing ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
-
Patients with histological verified CD20-positive B-Cell-Lymphomas of the following entities:
- Follicular lymphoma grade 1 and 2
- Immunocytoma and lymphoplasmocytic lymphoma
- Marginal zone lymphoma, nodal and generalised
- Mantle cell lymphoma
- lymphocytic lymphoma (CLL without leucaemic characteristics)
- non-specified/classified lymphomas of low malignancy
- No prior therapy with cytotoxics,interferon or monoclonal antibodies
- Need for therapy, except mantle cell lymphomas
- Stadium III or IV
- Written informed consent
- Performance status WHO 0-2
- Histology not older than 6 months
Exclusion Criteria:
- Patients not establishing all above mentioned prerequisites
- Option of a primary, potential curative radiation therapy
- Pretreatment except a unique local delimited radiation (radiation fiel not expanding two adjacent lymph node regions
-
Comorbidities excluding a study conform therapy:
- heart attack during the last 6 months
- severe, medicinal not adjustable hypertonia
- severe functional defects of the heart (NYHA III or IV)
- lung (WHO grade III or IV), liver or kidney (creatinine > 2 mg/dl, GOT + GPT or bilirubin 3 x ULN, except caused by lymphoma.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00991211
Germany | |
StiL Head Office; Justus-Liebig-University | |
Giessen, Germany, 35392 |
Principal Investigator: | Mathias Rummel, Dr. | Study Group of indolent Lymphom,as (StiL) |
Responsible Party: | Jurgen Barth, Study Group indolent Lymphomas (StiL), University of Giessen |
ClinicalTrials.gov Identifier: | NCT00991211 |
Other Study ID Numbers: |
NHL 1-2003 |
First Posted: | October 7, 2009 Key Record Dates |
Last Update Posted: | March 14, 2012 |
Last Verified: | October 2009 |
Comparison Bendamustine + Rituximab CHOP + Rituximab Progression free survival |
Overall survival Toxicity Safety |
Lymphoma Lymphoma, Non-Hodgkin Lymphoma, B-Cell, Marginal Zone Leukemia, Lymphocytic, Chronic, B-Cell Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Lymphoma, B-Cell Leukemia, B-Cell Leukemia, Lymphoid Leukemia Hematologic Diseases |
Chronic Disease Disease Attributes Pathologic Processes Cyclophosphamide Bendamustine Hydrochloride Doxorubicin Vincristine Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Antirheumatic Agents Antineoplastic Agents, Alkylating Alkylating Agents Molecular Mechanisms of Pharmacological Action Antineoplastic Agents |